LONDON and RALEIGH, NC, Oct. 26, 2022 (GLOBE NEWSWIRE) — Verona Pharma plc VRNA (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the third quarter ended September 30, 2022 on Wednesday, September 9th Investment Conference Call Community at 9:00am EST / 2:00pm GMT to discuss these financial results and provide a corporate update.
To participate, please dial one of the following numbers and ask to attend the Verona Pharma Call:
- +1-866-652-5200 for callers in the United States
- +1-412-317-6060 for international callers
A live webcast will be available via the “Events and Presentations” link on the Investors page of the Company’s website, www.veronapharma.comand audio playback is available for 90 days.
For more information please contact:
| Verona Pharma plc | US Phone: +1-833-417-0262 UK Tel: +44 (0)203 283 4200 |
| Victoria Stewart, Director of Investor Relations and Communications | IR@veronapharma.com |
| Argot partner (requests from US investors) |
Tel: +1-212-600-1902 verona@argotpartners.com |
| Kimberly Minarovich / Carrie McKim | |
| Optimal strategic communication (International media and European investor inquiries) |
Tel: +44 (0)203 882 9621 verona@optimumcomms.com |
| Mary Clark / Rebecca Noonan / Zoe Bolt | |
About Verona Pharma
Verona Pharma is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma’s product candidate, ensifentrin, has the potential to become the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory effects in one compound. The Company is evaluating nebulized ensifentrin in its Phase 3 clinical program ENHANCE (“Ensifentrin as Novel inHAled Nebulized COPD Therapy”) for COPD maintenance…
